IOPAMIDOL-300 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Iopamidol-300, and when can generic versions of Iopamidol-300 launch?
Iopamidol-300 is a drug marketed by Abbvie, Cook Imaging, Fresenius Kabi Usa, and Hospira. and is included in seven NDAs.
The generic ingredient in IOPAMIDOL-300 is iopamidol. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iopamidol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Iopamidol-300
A generic version of IOPAMIDOL-300 was approved as iopamidol by HAINAN POLY on February 27th, 2023.
Summary for IOPAMIDOL-300
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Clinical Trials: | 25 |
Patent Applications: | 3,980 |
Formulation / Manufacturing: | see details |
DailyMed Link: | IOPAMIDOL-300 at DailyMed |
Recent Clinical Trials for IOPAMIDOL-300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Chongqing Emergency Medical Center | N/A |
Army Medical Center of PLA | N/A |
M.D. Anderson Cancer Center | N/A |